EraCal Therapeutics Ltd. develops a oral-active anti-obesity drug, a first-in-class appetite suppressor. This new chemical entity emerged from EraCal’s drug discovery platform, which also forms the basis of a research collaboration with Novo Nordisk.

Cooperation possibilities

In vivo drug discovery and/or validation, CNS active compounds, small molecule chemistry.

Facts & figures
  • Type of organization
    Private company
  • Year of foundation
  • Number of employees in Switzerland
Key business